NMRA
Neumora Therapeutics, Inc. (NMRA) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at D+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C (2.4) | D- (0.9) | F (0.4) | C+ (2.6) | D+ (1.8) |
| 2026-11-06 | C+ (2.5) | C (2.3) | D- (0.9) | F (0.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-30 | C+ (2.5) | C (2.2) | D- (1.0) | F (0.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-23 | C+ (2.5) | C (2.2) | D- (0.9) | F (0.6) | C+ (2.6) | D+ (1.8) |
| 2026-10-16 | C+ (2.5) | C (2.2) | D- (0.9) | F (0.7) | C+ (2.6) | D+ (1.8) |